Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 16/20 | 1.00 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30076035 | 1.00 | GRIN2B (1.00) | GRIN2BGRM1MAPTCYP3A4CYP2D6 | |
| SCHEMBL16608231 | 1.00 | GRIN2B (1.00) | GRIN2BGRM1MAPTCYP3A4CYP2D6 | |
| SCHEMBL16608139 | 0.86 | GRIN2B (1.00) | GRIN2BGRM1CYP3A4CYP2D6GRM5 | |
| SCHEMBL16600992 | 0.86 | GRIN2B (1.00) | GRIN2BGRM1CYP3A4CYP2D6GRM5 | |
| SCHEMBL16601161 | 0.84 | GRIN2B (1.00) | GRIN2BGRM1CYP3A4CYP2D6GRM5 | |
| SCHEMBL30076068 | 0.84 | GRIN2B (1.00) | GRIN2BGRM1CYP3A4CYP2D6GRM5 | |
| SCHEMBL16608249 | 0.84 | GRIN2B (1.00) | GRIN2BGRM1CYP3A4CYP2D6GRM5 | |
| SCHEMBL16608241 | 0.82 | GRIN2B (1.00) | GRIN2B | |
| SCHEMBL16601291 | 0.82 | GRIN2B (1.00) | GRIN2B | |
| SCHEMBL30076114 | 0.82 | GRIN2B (1.00) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3036221-B1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS INC (US) | 2018-11-07 | — | — | EP | claimed |
| EP-3036221-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | Luc Therapeutics, Inc. (US) | 2016-06-29 | — | — | EP | claimed |
| US-20150225342-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | claimed |
| WO-2015048507-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | claimed |
| US-12161624-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-11116749-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | CADENT THERAPEUTICS, INC (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3461827-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | Cadent Therapeutics, Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20180325868-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2018-11-15 | — | — | US | disclosed |
| EP-3036221-B1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS INC (US) | 2018-11-07 | — | — | EP | disclosed |
| US-10052306-B2 | Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B | CADENT THERAPEUTICS, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20170071906-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | LUC THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9540324-B2 | Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B | LUC THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-3036221-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | Luc Therapeutics, Inc. (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20150225342-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| WO-2015048507-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10052306-B2 | Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN2B 4/4885GRM1 18/4885MAPT 1173/4885 |
| US-20170071906-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN2B 4/4885GRM1 18/4885MAPT 1173/4885 |
| US-20150225342-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN2B 4/4885GRM1 18/4885MAPT 1173/4885 |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN2B 4/4885GRM1 18/4885MAPT 1173/4885 |
| US-11116749-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN2B 4/4885GRM1 18/4885MAPT 1173/4885 |
| US-12161624-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN2B 4/4885GRM1 18/4885MAPT 1173/4885 |
| US-20180325868-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN2B 4/4885GRM1 18/4885MAPT 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.